Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Prostate Cancer Imaging Clear all
Completed Early Phase 1 Interventional

Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer

NCT04282824
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Monosodium Glutamate, Positron Emission Tomography
Procedure · Drug · Dietary Supplement
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 9, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)

NCT02384382
View directory record Official record
Conditions
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Detroit, Michigan • Farmington Hills, Michigan • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Sep 9, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

NCT02611882
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled HBED-CC PSMA, Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
Drug · Device
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 9, 2026, 8:14 PM EDT
Not listed Phase 1Phase 2 Interventional

64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer

NCT05286840
View directory record Official record
Conditions
Prostate Cancer
Interventions
64Cu-SAR-bisPSMA
Diagnostic Test
Lead sponsor
Luke Nordquist, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 9, 2026, 8:14 PM EDT
Terminated No phase listed Observational Results available

Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer

NCT01981109
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer
Interventions
Not listed
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
58
States / cities
Anchorage, Alaska • Tucson, Arizona • Atherton, California + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 9, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Cancer Localization in the Prostate With F-18 Fluorocholine Positron Emission Tomography

NCT01310192
View directory record Official record
Conditions
Prostate Cancer
Interventions
Fluourine-18 Fluoromethylcholine PET/CT Imaging
Device
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tripler AMC, Hawaii
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 9, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68-DOTATATE, Lutetium Lu 177 Dotatate, Positron Emission Tomography
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 9, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

NCT05438563
View directory record Official record
Conditions
Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Interventions
MRI-Guided Transurethral Ultrasound Ablation, Questionnaire Administration, Digital Rectal Examination, Cystoscopy, Biopsy, Bone Scan, PSMA PET Scan, Multiparametric Magnetic Resonance Imaging
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 9, 2026, 8:14 PM EDT
Withdrawn Phase 2 Interventional

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

NCT04910425
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Fluorine F 18 DCFPyL, Gadobenate Dimeglumine, Gadobutrol, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 9, 2026, 8:14 PM EDT
Active, not recruiting No phase listed Observational

Phase II Laser Focal Therapy of Prostate Cancer

NCT02243033
View directory record Official record
Conditions
Prostate Cancer
Interventions
MR-guided laser focal therapy
Device
Lead sponsor
HALO Diagnostics
Industry
Eligibility
45 Years to 90 Years · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2036
U.S. locations
1
States / cities
Indian Wells, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 9, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

NCT00588185
View directory record Official record
Conditions
Prostate Cancer
Interventions
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 9, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery

NCT02119858
View directory record Official record
Conditions
Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
indocyanine green solution, diffuse optical imaging, robot-assisted laparoscopic surgery, therapeutic lymphadenectomy
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 9, 2026, 8:14 PM EDT
Completed No phase listed Observational

Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy

NCT03535987
View directory record Official record
Conditions
Prostate Cancer
Interventions
myocardial PET imaging
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
51 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 9, 2026, 8:14 PM EDT
Recruiting Not applicable Interventional

Stratagen Quantitative Prostate MRI Platform Pilot Study

NCT06985238
View directory record Official record
Conditions
Prostate Cancer
Interventions
MRI
Device
Lead sponsor
Stratagen Bio, Inc.
Industry
Eligibility
40 Years to 90 Years · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Rochester, New York • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 9, 2026, 8:14 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging and Spectroscopy of the Prostate

NCT00590993
View directory record Official record
Conditions
Prostate Cancer
Interventions
MRI and MRSI
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Sep 9, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma

NCT03496844
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
F-18 fluciclovine-PET/CT scan
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 15, 2022 · Synced Sep 9, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Targeted Fusion Biopsy of the Prostate

NCT02744534
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
FACBC PET-CT Scan, Three-dimensional ultrasound-guided biopsy, Standard transrectal ultrasound (TRUS) guided biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 9, 2026, 8:14 PM EDT
Recruiting Phase 2 Interventional

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

NCT06499870
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Enzalutamide, Fluorine F 18 Piflufolastat, Image Guided Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Relugolix
Procedure · Drug · Other + 1 more
Lead sponsor
Sean Sachdev
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 9, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

MRI Based Active Selection for Treatment Trial

NCT02242773
View directory record Official record
Conditions
Prostate Cancer
Interventions
Multi-Parametric MRI, MRI-Guided Biopsy
Device
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 9, 2026, 8:14 PM EDT
Not listed Phase 2 Interventional

68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer

NCT02282137
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-PSMA
Drug
Lead sponsor
Ebrahim Delpassand
Other
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 9, 2026, 8:14 PM EDT
Recruiting No phase listed Observational

Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity

NCT07077239
View directory record Official record
Conditions
Prostate Cancer (CRPC)
Interventions
Not listed
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 9, 2026, 8:14 PM EDT
Not yet recruiting Not applicable Interventional

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Prostate Cancer

NCT07769372
View directory record Official record
Conditions
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy, Questionnaire Administration
Procedure · Other · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 9, 2026, 8:14 PM EDT
Completed Early Phase 1 Interventional

Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion

NCT04976257
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Angiogram, Catheterization, Gallium Ga-labeled PSMA-11, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Ryan Kohlbrenner, MD
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 9, 2026, 8:14 PM EDT
Active, not recruiting Not applicable Interventional

Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer

NCT05055843
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Carcinoma
Interventions
Magnetic Resonance Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 9, 2026, 8:14 PM EDT